Key result
Baseline hs-CRP > 3 mg/L linked to ~300% higher odds of appropriate ICD therapy.
Why the study?
Does elevated baseline hs-CRP (> 3 mg/L) predict appropriate ICD therapy in patients eligible for ICD implantation?
Population
100 patients eligible for implantable cardioverter-defibrillator (ICD) implantation
Comparison
Baseline high-sensitivity C-reactive protein > 3… vs Baseline high-sensitivity C-reactive protein ≤ 3…
Design
Cohort
Follow-up
24 months
Authors
Loading...
Hypothesis-generating for hs-CRP in ICD risk stratification; prospective trials needed before clinical adoption.
Cohort (n=100)
Does elevated baseline hs-CRP (> 3 mg/L) predict appropriate ICD therapy in patients eligible for ICD implantation?
Odds Ratio: 4 (95% CI 1.1–14.2)
p-value: p=0.03
Elevated preimplantation hs-CRP (>3 mg/L) is independently associated with a 4-fold increased risk of appropriate ICD therapy for ventricular arrhythmias.
Theuns et al. (2011) conducted a cohort in Eligible for implantable cardioverter-defibrillator (ICD) implantation (n=100). Baseline hs-CRP level > 3 mg/L vs. Baseline hs-CRP level ≤ 3 mg/L was evaluated on Appropriate ICD therapy triggered by ventricular arrhythmias (OR 4.0, 95% CI 1.1-14.2, p=0.03). Baseline hs-CRP > 3 mg/L was independently associated with appropriate ICD therapy triggered by ventricular arrhythmias over 24 months (OR 4.0; 95% CI 1.1-14.2; P=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: